Toll Free: 1-888-928-9744

Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Pipeline Review, H1 2016

Published: May 31, 2016 | Pages: 48 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Pipeline Review, H1 2016', provides in depth analysis on Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) targeted pipeline therapeutics. 

The report provides comprehensive information on the Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2)
- The report reviews Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) Overview 6 Therapeutics Development 7 Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Products under Development by Stage of Development 7 Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Products under Development by Therapy Area 8 Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Products under Development by Indication 9 Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Products under Development by Companies 13 Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 19 Assessment by Molecule Type 21 Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Companies Involved in Therapeutics Development 23 CJ HealthCare Corp. 23 MorphoSys AG 24 Novartis AG 25 Vicore Pharma AB 26 Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Drug Profiles 27 (amlodipine besylate + atorvastatin calcium + valsartan) - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 C-21 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 EMA-401 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 KDT-501 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 MOR-107 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 NP-6A - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Dormant Projects 36 Type-2 Angiotensin II Receptor (Angiotensin II Type-2 Receptor or AT2 or AGTR2) - Featured News & Press Releases 37 Feb 10, 2015: Spinifex Pharmaceuticals Enhances CMC Team With Two Senior Appointments 37 May 21, 2014: Lanthio Pharma receives Dutch Government loan of up to €3.6 million to develop novel therapy for lung fibrosis 38 Feb 05, 2014: Spinifex Pharmaceuticals' Phase 2 Results Published in The Lancet Show EMA401 to be Effective in Reducing Pain in Postherpetic Neuralgia 38 Oct 18, 2013: Spinifex Pharmaceuticals' EMA401 Named One of the Top Ten Neuroscience Projects to Watch 39 Mar 27, 2013: Spinifex Pharma Receives AUD1.5m In R&D Tax Incentive For Research Activities Related To Discovery Of Treatments For Pain 40 Feb 18, 2013: Vicore Pharma Announces Publication Of Article In Nature 40 Dec 10, 2012: Spinifex Pharma Starts Phase II Proof-of-concept Trial Of EMA401 In Chemotherapy-induced Peripheral Neuropathy 41 Nov 15, 2012: Vicore Pharma Announces Presentation Of Study Results Of C21 In Pulmonary Hypertension At 2012 American Heart Meeting 42 Nov 15, 2012: Vicore Pharma Announces Publication Of Study Results Of C21 In Spinal Cord Injury In Journal Neurobiology Of Disease 42 Aug 28, 2012: Spinifex Pharma Announces Positive Phase II Results For EMA401 In Postherpetic Neuralgia 43 Sep 19, 2011: Spinifex Announces Start Of Phase II Proof-of-Concept Trial Of EMA401 In Postherpetic Neuralgia 44 Sep 12, 2011: Spinifex Pharmaceuticals Presents New Data On EMA401 In Model Of Diabetic Neuropathy At 21st Annual NEURODIAB Meeting 44 Aug 23, 2011: Additional Funds To Broaden EMA401 Phase II Program 45 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 47 Disclaimer 48
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Products under Development by Companies, H1 2016 14 Products under Development by Companies, H1 2016 (Contd..1) 15 Assessment by Monotherapy/Combination Products, H1 2016 16 Number of Products by Stage and Mechanism of Action, H1 2016 18 Number of Products by Stage and Route of Administration, H1 2016 20 Number of Products by Stage and Molecule Type, H1 2016 22 Pipeline by CJ HealthCare Corp., H1 2016 23 Pipeline by MorphoSys AG, H1 2016 24 Pipeline by Novartis AG, H1 2016 25 Pipeline by Vicore Pharma AB, H1 2016 26 Dormant Projects, H1 2016 36


List of Figures
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Top 10 Indication, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 12 Assessment by Monotherapy/Combination Products, H1 2016 16 Number of Products by Mechanism of Actions, H1 2016 17 Number of Products by Stage and Mechanism of Actions, H1 2016 17 Number of Products by Routes of Administration, H1 2016 19 Number of Products by Stage and Routes of Administration, H1 2016 20 Number of Products by Molecule Types, H1 2016 21 Number of Products by Stage and Molecule Type, H1 2016 21

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demand

Read More...

Global electric water heaters market is expected to be valued at USD 29,322.4 million by 2022, as per a new research report by Radiant Insights, Inc. Escalating demand across extensive range of domestic applications is expected to drive demand. Evolv

Read More...

Global microcontroller market is estimated to be valued at USD 26.9 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing demand in key application areas such as automotive, consumer electronics and healthcare is expected to

Read More...

North America air conditioner market size is expected to be valued at USD 52,560.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing usage of energy efficient air conditioners owing to declining energy consumption rat

Read More...

Global Aerial Work Platform (AWP) truck market is expected to be valued at USD 8,003.7 million by 2022, as per a new research report by Radiant Insights, Inc. Rapid infrastructure growth due to rising real estate investment is expected to drive the i

Read More...
Choose License Type
Single User - US $3500
Multi User - US $7000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify